Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is also expanding its sales team, which may result in a temporary increase in cash burn, but overall the company has plenty of cash on hand. Additionally, the company's first quarter results in 2026 were strong, with a higher gross margin and increased guidance for key metrics in 2026. The company also remains on track to commercially launch its patch product by the end of 2027, potentially adding to its growth prospects.

Bears say

Beta Bionics is facing several potential risks, including the possibility of failing to gain market share or increase penetration in the pharmacy channel, delays in clinical development, and challenges with adoption in the Type 2 diabetes market. Additionally, initiatives proposed by CMS, shareholder dilution, and regulatory actions could also pose threats to the company's future growth and profitability. While the recent increase in pharmacy new starts and sales force expansion may provide short-term positives, the company's fundamental outlook is uncertain and may face downward pressure if these risks materialize.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.